2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)meth-oxy]phosphoryl]ethanamine CAS 918633-87-1

Product Description:

Product Name:

2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)meth-oxy]phosphoryl]ethanamine CAS NO: 918633-87-1

Synonyms:

HAP-302;

UNII-8A9RZ3HN8W;

TH-302;

Chemical & Physical Properties:

Appearance: Crystalline solid

Assay :≥98.0%

Density: 1.97

Boiling Point: 565.4±60.0℃ (Predicted)

PKa: 0.34±0.70 (Predicted)

Flash Point: 295.7±32.9℃

Vapor Pressure: 0.0±1.5 mmHg at 25℃

Index of Refraction: 1.662

Evofosfamide (INN, USAN; formerly known as TH-302) is an investigational hypoxia-activated prodrug that is in clinical development for cancer treatment. The prodrug is activated only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia.Evofosfamide is being evaluated in clinical trials for the treatment of multiple tumor types as a monotherapy and in combination with chemotherapeutic agents and other targeted cancer drugs. TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug (HAP) of bromo-isophosphoramide mustard. Studies have shown that TH-302 treatment exhibited hypoxia-selective cytotoxicity and DNA dama ge in human cancer cell.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.